Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up
Experimental Gilead and GSK HIV drugs are expected to compete; GSK R&D head resigns; Valeant subsidiary scores eye-drug approval
Sanofi to boost investment in biologics R&D; Sage's awareness campaign criticized; PatientsLikeMe poll finds 95% of patients want some costs of drugs covered
Novartis CAR-T drug boasts competitive response rates; WPP reports slowing sales for healthcare business; AZ sells migraine drug
Keytruda gets two new FDA approvals; lawmakers aim to speed up approval of generics; Incyte uses soap opera to spread rare-disease awareness
While investments in investigational lupus agents appear to be heating up, late-stage clinical failure continues to be a major hurdle to market entry.